These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 32092539)

  • 41. It is too soon to attribute ADE to COVID-19.
    Sharma A
    Microbes Infect; 2020; 22(4-5):158. PubMed ID: 32268188
    [No Abstract]   [Full Text] [Related]  

  • 42. Iron: Innocent bystander or vicious culprit in COVID-19 pathogenesis?
    Edeas M; Saleh J; Peyssonnaux C
    Int J Infect Dis; 2020 Aug; 97():303-305. PubMed ID: 32497811
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Microvascular injury and hypoxic damage: emerging neuropathological signatures in COVID-19.
    Jaunmuktane Z; Mahadeva U; Green A; Sekhawat V; Barrett NA; Childs L; Shankar-Hari M; Thom M; Jäger HR; Brandner S
    Acta Neuropathol; 2020 Sep; 140(3):397-400. PubMed ID: 32638079
    [No Abstract]   [Full Text] [Related]  

  • 44. Antibody-Dependent Enhancement and the Critical Pattern of COVID-19: Possibilities and Considerations.
    Farshadpour F; Taherkhani R
    Med Princ Pract; 2021; 30(5):422-429. PubMed ID: 33882487
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evidence of protective role of Ultraviolet-B (UVB) radiation in reducing COVID-19 deaths.
    Moozhipurath RK; Kraft L; Skiera B
    Sci Rep; 2020 Oct; 10(1):17705. PubMed ID: 33077792
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechano-genomic regulation of coronaviruses and its interplay with ageing.
    Uhler C; Shivashankar GV
    Nat Rev Mol Cell Biol; 2020 May; 21(5):247-248. PubMed ID: 32242128
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibody-Dependent Enhancement of SARS-CoV-2 Infection Is Mediated by the IgG Receptors FcγRIIA and FcγRIIIA but Does Not Contribute to Aberrant Cytokine Production by Macrophages.
    Maemura T; Kuroda M; Armbrust T; Yamayoshi S; Halfmann PJ; Kawaoka Y
    mBio; 2021 Oct; 12(5):e0198721. PubMed ID: 34579572
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ADE and hyperinflammation in SARS-CoV2 infection- comparison with dengue hemorrhagic fever and feline infectious peritonitis.
    Cloutier M; Nandi M; Ihsan AU; Chamard HA; Ilangumaran S; Ramanathan S
    Cytokine; 2020 Dec; 136():155256. PubMed ID: 32866898
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immune dysfunction leads to mortality and organ injury in patients with COVID-19 in China: insights from ERS-COVID-19 study.
    Li D; Chen Y; Liu H; Jia Y; Li F; Wang W; Wu J; Wan Z; Cao Y; Zeng R
    Signal Transduct Target Ther; 2020 May; 5(1):62. PubMed ID: 32371949
    [No Abstract]   [Full Text] [Related]  

  • 50. The Role of Antibodies in the Treatment of SARS-CoV-2 Virus Infection, and Evaluating Their Contribution to Antibody-Dependent Enhancement of Infection.
    Farouq MAH; Acevedo R; Ferro VA; Mulheran PA; Al Qaraghuli MM
    Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682757
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Theoretical Explanation for the Rarity of Antibody-Dependent Enhancement of Infection (ADE) in COVID-19.
    Boldova AE; Korobkin JD; Nechipurenko YD; Sveshnikova AN
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232664
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evolving understanding of antibody-dependent enhancement (ADE) of SARS-CoV-2.
    Yang Y; Xu F
    Front Immunol; 2022; 13():1008285. PubMed ID: 36330519
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibody-dependent enhancement of virus infection and disease: implications in COVID-19.
    Shukla AK; Misra S
    J Basic Clin Physiol Pharmacol; 2022 Jan; 33(1):13-16. PubMed ID: 34995021
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antibody dependent enhancement: Unavoidable problems in vaccine development.
    Xu L; Ma Z; Li Y; Pang Z; Xiao S
    Adv Immunol; 2021; 151():99-133. PubMed ID: 34656289
    [TBL] [Abstract][Full Text] [Related]  

  • 55. High COVID-19 mortality in the UK: lessons to be learnt from Hubei province: are under-detected 'silent hypoxia' and subsequently low admission rate to blame?
    Deng J; Peng ZY; Wen ZX; Dong GQ; Xie MX; Xu GG
    QJM; 2020 Dec; 113(12):854-855. PubMed ID: 32866270
    [No Abstract]   [Full Text] [Related]  

  • 56. Mathematical modeling the dynamics of SARS-CoV-2 infection with antibody-dependent enhancement.
    Song H; Yuan Z; Liu S; Jin Z; Sun G
    Nonlinear Dyn; 2023; 111(3):2943-2958. PubMed ID: 36246668
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunoregulation with mTOR inhibitors to prevent COVID-19 severity: A novel intervention strategy beyond vaccines and specific antiviral medicines.
    Zheng Y; Li R; Liu S
    J Med Virol; 2020 Sep; 92(9):1495-1500. PubMed ID: 32410266
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunity after COVID-19: Protection or sensitization?
    Danchin A; Turinici G
    Math Biosci; 2021 Jan; 331():108499. PubMed ID: 33129826
    [TBL] [Abstract][Full Text] [Related]  

  • 59. COVID-19 Vaccines: Should We Fear ADE?
    Halstead SB; Katzelnick L
    J Infect Dis; 2020 Nov; 222(12):1946-1950. PubMed ID: 32785649
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies.
    Lee WS; Wheatley AK; Kent SJ; DeKosky BJ
    Nat Microbiol; 2020 Oct; 5(10):1185-1191. PubMed ID: 32908214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.